SCHEMBL2857712

SCHEMBL2857712

Cc1cc(F)c(C(=O)c2cccc(F)c2)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
POLB P06746 1/20 0.45
PARP1 P09874 1/20 0.44
KMT2A Q03164 4/20 0.43
LMNA P02545 2/20 0.41
TSHR P16473 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KCNH2 Q12809 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866787 0.86 CES2 (0.50) CES2CES1HDAC1HDAC6POLB
SCHEMBL2867334 0.82 NPC1 (0.49) CES2CES1HDAC1HDAC6LMNA
SCHEMBL17235788 0.77 DGAT1 (0.53) CES2CES1HDAC1HDAC6POLB
SCHEMBL9397130 0.76 POLB (0.54) CES2CES1HDAC1HDAC6POLB
SCHEMBL14415761 0.76 CES2 (0.53) CES2CES1HDAC1HDAC6POLB
SCHEMBL14415753 0.75 CES2 (0.52) CES2CES1HDAC1HDAC6POLB
SCHEMBL17235856 0.73 CES2 (0.53) CES2CES1HDAC1HDAC6PARP1
SCHEMBL1258944 0.73 CES2 (0.74) CES2CES1HDAC1HDAC6POLB
SCHEMBL15608356 0.73 PARP1 (0.50) CES2CES1HDAC1HDAC6POLB
SCHEMBL2857642 0.73 CES2 (0.49) CES2CES1HDAC1HDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CES2 2171/4885CES1 2628/4885HDAC1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.